Grifols achieves its highest-ever score in the 2024 S&P Global Sustainability Assessment

Barcelona, Spain, October 15, 2024 – Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that it has achieved its highest-ever S&P Global ESG score. The company’s rating of 70 points marks a seven-point increase over last year's results and highlights the company’s significant progress and unwavering commitment to sustainability.

In terms of governance, S&P has acknowledged Grifols’ efforts to foster a more responsible and sustainable supply chain. Additionally, the company continues to earn the highest score for its sustainability reporting and business ethics.

Regarding its environmental approach, Grifols has set more ambitious targets to accelerate its transition to a low-carbon economy. S&P has recognized Grifols’ progress in climate strategy, while maintaining the highest score in climate governance and risk management.

With respect to the social strategy, S&P has rewarded Grifols’ commitment to ensuring a safe and healthy workplace for all employees, as well as its continued dedication to upholding and promoting human rights across all areas of operation. In addition, S&P has once again awarded the company the highest possible score for its commitment to ethical marketing. 

This achievement underscores Grifols’ unwavering commitment to excellence in environmental, social and governance practices. As the company continues to advance its sustainability goals, it remains focused on driving long-term value and making a lasting impact toward a more sustainable, ethical and resilient future for all stakeholders.

For more information on Grifols’ ESG initiatives and progress, please visit Sustainability | Grifols and read more about the company’s commitment in the Biopharmaceutical Industry Sustainability Reports | Grifols.